Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1992 7
1993 7
1994 5
1995 2
1996 9
1997 6
1998 4
1999 6
2000 7
2001 1
2002 1
2003 4
2004 2
2005 3
2006 8
2007 7
2008 7
2009 4
2010 6
2011 6
2012 9
2013 5
2014 8
2015 5
2016 8
2017 5
2018 7
2019 8
2020 8
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

161 results
Results by year
Filters applied: . Clear all
Page 1
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J, Shannon CM, Baumann K, Rau J, Harter P, Joly F, Sehouli J, Canzler U, Schmalfeldt B, Dean AP, Hein A, Zeimet AG, Hanker LC, Petit T, Marmé F, El-Balat A, Glasspool R, de Gregorio N, Mahner S, Meniawy TM, Park-Simon TW, Mouret-Reynier MA, Costan C, Meier W, Reinthaller A, Goh JC, L'Haridon T, Baron Hay S, Kommoss S, du Bois A, Kurtz JE; AGO-OVAR 2.21/ENGOT-ov 18 Investigators. Pfisterer J, et al. Among authors: zeimet ag. Lancet Oncol. 2020 May;21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. Epub 2020 Apr 16. Lancet Oncol. 2020. PMID: 32305099 Clinical Trial.
Hopes and failures in front-line ovarian cancer therapy.
Tsibulak I, Zeimet AG, Marth C. Tsibulak I, et al. Among authors: zeimet ag. Crit Rev Oncol Hematol. 2019 Nov;143:14-19. doi: 10.1016/j.critrevonc.2019.08.002. Epub 2019 Aug 14. Crit Rev Oncol Hematol. 2019. PMID: 31449982 Free article. Review.
Immunotherapy in ovarian cancer: fake news or the real deal?
Marth C, Wieser V, Tsibulak I, Zeimet AG. Marth C, et al. Among authors: zeimet ag. Int J Gynecol Cancer. 2019 Jan;29(1):201-211. doi: 10.1136/ijgc-2018-000011. Int J Gynecol Cancer. 2019. PMID: 30640705 Review.
Ovarian Cancer Stem Cell Heterogeneity.
Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG. Hatina J, et al. Among authors: zeimet ag. Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12. Adv Exp Med Biol. 2019. PMID: 31134503 Review.
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.
Mahner S, Meier W, du Bois A, Brown C, Lorusso D, Dell'Anna T, Cretin J, Havsteen H, Bessette P, Zeimet AG, Vergote I, Vasey P, Pujade-Lauraine E, Gladieff L, Ferrero A. Mahner S, et al. Among authors: zeimet ag. Eur J Cancer. 2015 Feb;51(3):352-8. doi: 10.1016/j.ejca.2014.11.017. Epub 2014 Dec 17. Eur J Cancer. 2015. PMID: 25534295 Clinical Trial.
Clinical Impact of RANK Signalling in Ovarian Cancer.
Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG. Wieser V, et al. Among authors: zeimet ag. Cancers (Basel). 2019 Jun 8;11(6):791. doi: 10.3390/cancers11060791. Cancers (Basel). 2019. PMID: 31181781 Free PMC article.
161 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page